Comparison · NCT01666444-sae
Pegylated Liposomal Doxorubicin (PLD) + Placebo vs Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pegylated Liposomal Doxorubicin (PLD) + Placebo vs Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX): serious adverse events. Trial comparisons, record NCT01666444-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01666444-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.204 | 0.147 | 0.276 | wilson | |
| Risk in group 2 | 0.245 | 0.182 | 0.32 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0408 | -0.135 | 0.0547 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.833 | 0.544 | 1.28 | log | |
| Odds ratio, group 1 over group 2 | 0.791 | 0.456 | 1.37 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Pegylated Liposomal Doxorubicin (PLD) + Placebo than on Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX) | 24.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pegylated Liposomal Doxorubicin (PLD) + Placebo | Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 plus placebo | 30 | 147 | EG000 |
| Group 2 | Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX) | Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 plus VTX-2337 3.0 mg/m2 | 36 | 147 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse Event assessments began with initiation of any study treatment up until 30 days following the last cycle of treatment.
Source ClinicalTrials.gov
Trial
- Title
- VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- NCT number
- NCT01666444
- Phases
- PHASE2
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
- Lead sponsor
- Celgene
- Results first posted
- 2019-09-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01666444?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01666444-sae